In This Section      

Ciccarone Articles

Ciccarone Center Research



Landmark Articles

The relationship of cigarette smoking with inflammation and subclinical vascular disease: The Multi-Ethnic Study of Atherosclerosis.
By: McEvoy J, Nasir K, DeFilippis A, Lima J, Bluemke D, Hundley WG, Barr RG, Budoff M, Szklo M, Navas-Acien A, Polak J, Blumenthal R, Post W, Blaha M.

We sought to assess the impact of smoking status, cumulative pack-years, and time since cessation (the latter in former smokers only) on 3 important domains of cardiovascular disease: inflammation, vascular dynamics and function, and subclinical atherosclerosis. These findings expand our understanding of the harmful effects of smoking and help explain the cardiovascular benefits of smoking cessation.

Read on Pubmed
Novel biomarkers and risk factors.
By: Cheng HG, Martin SS, Jones SR.
Hot, cool, cold: The future of phospholipid A2 as a therapeutic target for CHD.
By: Houston B, Martin SS.
This article reviewed the state-of-the-art research involving inhibition of phospholipid A2 to reduce subsequent cardiovascular events.
Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome.
By: Jamal O, Aneni EC, Shaharyar S, Ali SS, Parris D, McEvoy JW, Veledar E, Blaha MJ, Blumenthal RS, Agatston AS, Coceicao RD, Feldman T, Carvalho JA, Santos RD, Nasir K.

Emerging data suggests that the combination of smoking and metabolic syndrome (MetS) markedly increases cardiovascular disease risk well beyond that of either condition. In this study we assess if this interaction can be explained by an additive increase in the risk of systemic inflammation by MetS and cigarette smoking. The study demonstrates an additive effect of cigarette smoking on the risk of systemic inflammation in MetS thus highlighting the need for determining smoking status among those with MetS and aggressively targeting smoking cessation in this population.

Read on Pubmed
Letter by Jones et al regarding article, “Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.”
By: Jones SR, Martin SS, Brinton EA.
Read on Pubmed
Associations of Pentraxin 3 with cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis.
By: Jenny NS, Blumenthal RS, Kronmal RA, Rotter JI, Siscovick DS, Psaty BM.
In a study of apparently healthy adults, Pentraxin 3 was associated with CVD risk factors, subclinical CVD, CAC and incident coronary heart disease events independent of C-reactive protein (CRP) and CVD risk factors. These results support the hypothesis that PTX3 reflects different aspects of inflammation than CRP and may provide additional insight into the development and progression of atherosclerosis.
Read on Pubmed
Critical review of high-sensitivity C-reactive protein and coronary artery calcium for the guidance of statin allocation: head-to-head comparison of the JUPITER and St. Francis Heart Trials.
By: Kim J, McEvoy JW, Nasir K, Budoff MJ, Arad Y, Blumenthal RS, Blaha MJ.
This analysis looks at the strengths and limitations of two large trials of statin therapy based on persons with an elevated hsCRP, CAC score, or both.
Read on Pubmed
C-reactive protein is independently associated with coronary atherosclerosis burden among octogenarians.
By: Quaglia LA, Freitas WM, Soares AA, Santos RD, Nadruz W, Blaha MJ, Coelho OR, Blumenthal R, Agatston A, Nasir K, Sposito AC.
We examined measures of inflammation and subclinical atherosclerosis in persons with successful cardiovascular aging.
Read on Pubmed
Association between resting heart rate and inflammatory biomarkers (high-sensitivity C-reactive protein, interleukin-6, and fibrinogen): from the Multi-Ethnic Study of Atherosclerosis.
By: Whelton SP, Narla V, Blaha MJ, Nasir K, Blumenthal RS, Jenny NS, Al-Mallah MH, Michos ED.
Heart rate (HR) at rest is associated with adverse cardiovascular events; however, the biologic mechanism for the relation is unclear. An increased HR at rest was associated with a higher level of inflammation among an ethnically diverse group of subjects without known cardiovascular disease.
Read on Pubmed
Subclinical cardiovascular disease in plaque psoriasis: association or causal link?
By: Shaharyar S, Warraich H, McEvoy JW, Oni E, Ali SS, Karim A, Jamal O, Blaha MJ, Blumenthal RS, Fialkow J, Cury R, Budoff MJ, Agatston AA, Nasir K.

Since patients with psoriasis have an increased burden of subclinical atherosclerosis and endothelial dysfunction, those with greater severity and/or disease duration should be targeted for primary screening for cardiovascular disease risk reduction.

Read on Pubmed